Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026
Company Deals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Dizal Pharmaceutical’s Surufatinib Earns CDE Consideration for Breakthrough Therapy in EGFR exon20ins NSCLC

Fineline Cube Oct 3, 2024

Dizal Pharmaceutical, a biopharmaceutical company based in China, has announced that the Center for Drug...

Company Drug

Hengrui Pharmaceuticals’ HR19042 Capsules Designated as Breakthrough Therapy for Autoimmune Hepatitis by China NMPA

Fineline Cube Oct 2, 2024

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has recently...

Company Drug

NMPA Clears AbbVie’s ABBV-706 for Clinical Trials Targeting SCLC and Neuroendocrine Tumors

Fineline Cube Oct 2, 2024

The China National Medical Products Administration (NMPA) has granted clinical trial approval to ABBV-706, a...

Company Deals

Jiangsu Alphamab Biopharmaceuticals Partners with Shanghai Jinmant Biotech for JSKN003 ADC

Fineline Cube Oct 2, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced that its wholly-owned...

Company Drug

CStone Pharmaceuticals’ Partner HengRui Medicine Launches Phase III Trial for CTLA-4 Antibody in HCC

Fineline Cube Oct 2, 2024

CStone Pharmaceuticals (HKG: 2616), an innovation-driven biopharmaceutical company focused on the development of oncology drugs,...

Company

Zephyrm Bioscience Aims for HKEX Main Board with Innovative Cell Therapy Products

Fineline Cube Oct 1, 2024

Zephyrm Bioscience Limited (hereinafter referred to as “Zephyrm Bio”) officially submitted its prospectus to the...

Company Drug

Akeso Biopharma’s Cadonilimab Secures NMPA Approval for Gastric Cancer Indication

Fineline Cube Oct 1, 2024

Akeso Biopharma Inc. (HKG: 9926) announced that its self-developed PD-1/CTLA-4 bispecific antibody, Cadonilimab injection (AK104),...

Company Deals

Alphamab Oncology Strikes Licensing Deal with CSPC Pharma for HER2 Targeted ADC in China

Fineline Cube Sep 30, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a licensing...

Company Drug

Sichuan Biokin’s Partner Bristol-Myers Squibb Gets FDA Nod for Bispecific ADC Study

Fineline Cube Sep 30, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced that its...

Company Drug

J&J’s Carvykti Shows 45% Reduced Risk of Death in Multiple Myeloma Patients, Landmark Trial Data Reveals

Fineline Cube Sep 30, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a U.S.-based healthcare conglomerate, has released new clinical trial...

Company Drug

Yabao Pharmaceutical’s SY-009 Receives NMPA Approval for Phase II Clinical Trial in Constipation

Fineline Cube Sep 30, 2024

Yabao Pharmaceutical Group Co., Ltd (SHA: 600351), a Chinese pharmaceutical company, has announced that SY-009...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Clinical Trial of TSLP-Targeted Asthma Treatment

Fineline Cube Sep 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company R&D

Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem

Fineline Cube Sep 30, 2024

Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced...

Company Drug

Huadong Medicine Gets NMPA Green Light for Clinical Trials of Roflumilast Cream

Fineline Cube Sep 30, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...

Company Medical Device

LenoMed Medical’s Touch-Insulin Pump Receives NMPA Approval, Aids China’s Diabetes Management

Fineline Cube Sep 30, 2024

Shanghai-based LenoMed Medical, a medical device platform company backed by Legend Capital and Legend Star,...

Company Deals

Mindray Bio-Medical Partners with Nanjing Drum Tower Hospital to Boost Clinical Research

Fineline Cube Sep 30, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical equipment provider, has entered...

Company Drug

Qilu Pharmaceutical’s QL1706 Receives NMPA Conditional Approval for Cervical Cancer Treatment

Fineline Cube Sep 30, 2024

Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its combination drug QL1706, comprising iparomlimab...

Policy / Regulatory

Study Predicts 2025 Medicare Part D Negotiation Candidates, With Novo Nordisk’s Semaglutide Leading the List

Fineline Cube Sep 29, 2024

Researchers in the U.S. have compiled a list of drugs that are anticipated to be...

Company Drug

Dupixent Secures Back-to-Back COPD Approvals from US FDA and China NMPA

Fineline Cube Sep 29, 2024

Regeneron (NASDAQ: REGN), a leading biopharmaceutical company based in the U.S., in collaboration with its...

Company Drug

AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA

Fineline Cube Sep 29, 2024

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...

Posts pagination

1 … 315 316 317 … 691

Recent updates

  • China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
  • Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
  • Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
  • Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
  • CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.